Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores

A prospective randomized trial

Orhan Bukulmez, Atakan Al, Hakan Gurdal, Hakan Yarali, Berna Ulug, Timur Gurgan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: To evaluate the effects of continuous hormone replacement therapy (HRT) regimens on platelet-tritiated (3H-) imipramine binding (Bmax) and mood. Design: Prospective randomized study. Setting: University hospital. Patient(s): Sixty postmenopausal patients. Intervention(s): Randomization to 3 months of daily treatment with tibolone and conjugated equine estrogen (CEE) .625 mg combined either with 2.5 or 5 mg of medroxyprogesterone acetate (MPA). The inclusion criteria-matched patients declined for HRT were prescribed daily alendronate. Pre- and posttreatment blood sampling for Bmax and mood evaluation with the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI) were done. Main Outcome Measure(s): Pre- and posttreatment Bmax and mood scores. Result(s): As compared with baseline, both CEE+MPA regimens and tibolone significantly increased Bmax. The comparisons of percent change from baseline Bmax for the CEE+MPA and tibolone groups were similar. All three HRT regimens improved the BDI significantly, while there were no significant changes in the STAI. In the alendronate group, there were no significant changes in both pre- and posttreatment Bmax and mood scores. Conclusion(s): Continuous treatment with CEE+MPA and tibolone increases platelet 3H-imipramine binding and improves mood. Mood-enhancing effects of tibolone may occur through the serotonergic system, as is the case with estrogen.

Original languageEnglish (US)
Pages (from-to)737-743
Number of pages7
JournalFertility and Sterility
Volume75
Issue number4
DOIs
StatePublished - 2001

Fingerprint

tibolone
Imipramine
Hormone Replacement Therapy
Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Blood Platelets
Alendronate
Equipment and Supplies
Anxiety
Depression
Random Allocation
Estrogens
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • Conjugated estrogens
  • Hormone replacement therapy
  • Medroxyprogesterone acetate
  • Mood
  • Platelet-tritiated imipramine binding
  • Tibolone

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores : A prospective randomized trial. / Bukulmez, Orhan; Al, Atakan; Gurdal, Hakan; Yarali, Hakan; Ulug, Berna; Gurgan, Timur.

In: Fertility and Sterility, Vol. 75, No. 4, 2001, p. 737-743.

Research output: Contribution to journalArticle

@article{bc0420014bf64781a2daddbf99ae2ee4,
title = "Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: A prospective randomized trial",
abstract = "Objective: To evaluate the effects of continuous hormone replacement therapy (HRT) regimens on platelet-tritiated (3H-) imipramine binding (Bmax) and mood. Design: Prospective randomized study. Setting: University hospital. Patient(s): Sixty postmenopausal patients. Intervention(s): Randomization to 3 months of daily treatment with tibolone and conjugated equine estrogen (CEE) .625 mg combined either with 2.5 or 5 mg of medroxyprogesterone acetate (MPA). The inclusion criteria-matched patients declined for HRT were prescribed daily alendronate. Pre- and posttreatment blood sampling for Bmax and mood evaluation with the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI) were done. Main Outcome Measure(s): Pre- and posttreatment Bmax and mood scores. Result(s): As compared with baseline, both CEE+MPA regimens and tibolone significantly increased Bmax. The comparisons of percent change from baseline Bmax for the CEE+MPA and tibolone groups were similar. All three HRT regimens improved the BDI significantly, while there were no significant changes in the STAI. In the alendronate group, there were no significant changes in both pre- and posttreatment Bmax and mood scores. Conclusion(s): Continuous treatment with CEE+MPA and tibolone increases platelet 3H-imipramine binding and improves mood. Mood-enhancing effects of tibolone may occur through the serotonergic system, as is the case with estrogen.",
keywords = "Conjugated estrogens, Hormone replacement therapy, Medroxyprogesterone acetate, Mood, Platelet-tritiated imipramine binding, Tibolone",
author = "Orhan Bukulmez and Atakan Al and Hakan Gurdal and Hakan Yarali and Berna Ulug and Timur Gurgan",
year = "2001",
doi = "10.1016/S0015-0282(01)01669-7",
language = "English (US)",
volume = "75",
pages = "737--743",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores

T2 - A prospective randomized trial

AU - Bukulmez, Orhan

AU - Al, Atakan

AU - Gurdal, Hakan

AU - Yarali, Hakan

AU - Ulug, Berna

AU - Gurgan, Timur

PY - 2001

Y1 - 2001

N2 - Objective: To evaluate the effects of continuous hormone replacement therapy (HRT) regimens on platelet-tritiated (3H-) imipramine binding (Bmax) and mood. Design: Prospective randomized study. Setting: University hospital. Patient(s): Sixty postmenopausal patients. Intervention(s): Randomization to 3 months of daily treatment with tibolone and conjugated equine estrogen (CEE) .625 mg combined either with 2.5 or 5 mg of medroxyprogesterone acetate (MPA). The inclusion criteria-matched patients declined for HRT were prescribed daily alendronate. Pre- and posttreatment blood sampling for Bmax and mood evaluation with the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI) were done. Main Outcome Measure(s): Pre- and posttreatment Bmax and mood scores. Result(s): As compared with baseline, both CEE+MPA regimens and tibolone significantly increased Bmax. The comparisons of percent change from baseline Bmax for the CEE+MPA and tibolone groups were similar. All three HRT regimens improved the BDI significantly, while there were no significant changes in the STAI. In the alendronate group, there were no significant changes in both pre- and posttreatment Bmax and mood scores. Conclusion(s): Continuous treatment with CEE+MPA and tibolone increases platelet 3H-imipramine binding and improves mood. Mood-enhancing effects of tibolone may occur through the serotonergic system, as is the case with estrogen.

AB - Objective: To evaluate the effects of continuous hormone replacement therapy (HRT) regimens on platelet-tritiated (3H-) imipramine binding (Bmax) and mood. Design: Prospective randomized study. Setting: University hospital. Patient(s): Sixty postmenopausal patients. Intervention(s): Randomization to 3 months of daily treatment with tibolone and conjugated equine estrogen (CEE) .625 mg combined either with 2.5 or 5 mg of medroxyprogesterone acetate (MPA). The inclusion criteria-matched patients declined for HRT were prescribed daily alendronate. Pre- and posttreatment blood sampling for Bmax and mood evaluation with the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI) were done. Main Outcome Measure(s): Pre- and posttreatment Bmax and mood scores. Result(s): As compared with baseline, both CEE+MPA regimens and tibolone significantly increased Bmax. The comparisons of percent change from baseline Bmax for the CEE+MPA and tibolone groups were similar. All three HRT regimens improved the BDI significantly, while there were no significant changes in the STAI. In the alendronate group, there were no significant changes in both pre- and posttreatment Bmax and mood scores. Conclusion(s): Continuous treatment with CEE+MPA and tibolone increases platelet 3H-imipramine binding and improves mood. Mood-enhancing effects of tibolone may occur through the serotonergic system, as is the case with estrogen.

KW - Conjugated estrogens

KW - Hormone replacement therapy

KW - Medroxyprogesterone acetate

KW - Mood

KW - Platelet-tritiated imipramine binding

KW - Tibolone

UR - http://www.scopus.com/inward/record.url?scp=0035056978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035056978&partnerID=8YFLogxK

U2 - 10.1016/S0015-0282(01)01669-7

DO - 10.1016/S0015-0282(01)01669-7

M3 - Article

VL - 75

SP - 737

EP - 743

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 4

ER -